Brain Response in Some Systemic Immune Condition- Toxicological Aspects

Luisetto M1*, Behzad NA2 and Ghulam RM3

1Department of Applied pharmacologist, Italy
2Department of Nano Drug Delivery, USA
3Department of Medical & Health Sciences, Peoples University of Medical & Health Sciences for Woman, Pakistan

*Corresponding author: Luisetto M, Applied pharmacologist, European specialist in lab medicine, hospital pharmacist manager, Italy

Submission: December 12, 2017; Published: January 29, 2018

Abstract

From biomedical literature "autism disorder are involved in young patient, that have abnormalities (Imaging, histology) in some brain areas, and a compiles symptomatology. Genetic and environment can produce some unbalances in brain grow and immunitary situation is involved. Apoptotic signal contribute in brain growth and immunologic shock can unbalance the environment producing abnormalities." We can see that some pharmacological molecules are been introduced in therapy in some brain pathologies with a specific mechanism: modulating the immune systems. We can see that some systemic immune modifications can unbalance this systems producing pharmacological effect in local place (as Brain). We can observe this phenomenon like a kind of toxicity that can be deeply investigated to discover new Pharmacological strategies. Aim of this work is to observe this kind of pathologies under a specific immune-toxicological aspect. We think that in this field are needed deeply new approaches in order to adequately focus this kind of disorder. A different way to set this kind of pathologies can help in searching new pharmacological strategies.

Keywords: Toxicology; Brain pathology; Immune status; New pharmacological strategies

Introduction

Under the need of new research hypothesys to verify the pathogenesys of some brain disorder we try to observe under a specific immune- toxicological aspect in order to search new pharmacological strategies.

We start this work observing the SM pathology, that is consider an organ specific disease. In this kind of pathology we have a specific role of Flogosis events and leucocyte migration, amplification of immune reactions with enrollment of monocytes, macrophages, TCELLS cytotoxic and plasma cells from periferical blood.

Currently in Therapy SM some strategies in use as immune modifier

a. Metilprednisolon.

b. Fingolimod, receptor modulator sfingosin-1-fosfate (S1P), localized on lymphocyte surfaces and able to across the haematencefalic barrier.

c. Antagonists S1P receptors in lymphocyte, inhibit lymphocyte properties of come out from limphonodes (redistributions) with reducing infiltration of lymphocytes in SNC (involved in nerve Flogosis and tissue damage). In 4-6 hours after sub ministration we can observe reduction of lymphocytes in periferical blood (75%). And in 2 weeks 30% in reducing lymphocyte counts.

After stopped sub ministration increase perifericalillymphocite (normal level in 1-2 months)

a. Interferon beta reduces SNC Flogosis; reduce lymphocyte T activation, and pass through the SNC tissue.

b. Mitoxantron immunosuppressor use per SM in fasi RR, SP, Ciclofosfamide etc.

c. Natalizumab directed to α 4 della α 4 β 1 integrin chain, and block binding of “Very Late Antigen” della α 4 β1 integrina (VLA4) expressed in all leucocytes, with vascular cell molecule of adhesion (VCAM), inhibits the binding of leucocyte α 4-positive with la Fibronectina (antiapoptoticfor i lymphocyte T).

d. Modulate lymph T transfer from periferical blood to tissue, lymphocyte T apoptosis, and leucocitary activation. In animal model using MRI was observed reducing in tissue migration of leucocyte and reduced plaques after multiple sub ministration.

e. But other molecules are in use in this pathology (old and new) related the specific phases of disease and different kind of disease.

Material and Methods

This review work has been implemented with an observational and review approach we have analyzed some relevant bibliography
in order to verify the general immune status influences with some local situations and the relationship.

**Results**

From bio-medical literature we can see

According to Bilbo SD et al. “The brain, endocrine, and immune systems are inextricably linked. Immune molecules have a powerful impact on neuroendocrine function, including hormone-behavior interactions, during health as well as sickness. Similarly, alterations in hormones, such as during stress, can powerfully impact immune function or reactivity. These functional shifts are evolved, adaptive responses that organize changes in behavior and mobilize immune resources, but can also lead to pathology or exacerbate disease if prolonged or exaggerated. The developing brain in particular is exquisitely sensitive to both endogenous and exogenous signals, and increasing evidence suggests the immune system has a critical role in brain development and associated behavioral outcomes for the life of the individual. Indeed, there are associations between many neuropsychiatric disorders and immune dysfunction, with a distinct etiology in neurodevelopment. The goal of this review is to describe the important role of the immune system during brain development, and to discuss some of the many ways in which immune activation during early brain development can affect the later-life outcomes of neural function, immune function, mood and cognition [1].”

Kappos L et al. [2] wrote that

“Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 studies of multiple sclerosis. In our 24-month, double-blind, randomized study, we enrolled patients who had relapsing-remitting multiple sclerosis, were 18 to 55 years of age, had a score from 0 to 10, with higher scores indicating greater disability), and had had one or more relapses in the previous year or two or more in the previous 2 years. Patients received oral fingolimod at a dose of 0.5 mg or 1.25 mg daily or placebo. End points included the annualized relapse rate (the primary end point) and the time to disability progression (a secondary end point). A total of 1033 of the 1272 patients (81.2%) completed the study. The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo). Fingolimod at doses of 0.5 mg and 1.25 mg significantly reduced the risk of disability progression over the 24-month period (hazard ratio, 0.70 and 0.68, respectively; P=0.02 vs. placebo, for both comparisons).

The cumulative probability of disability progression (confirmed after 3 months) was 17.7% with 0.5 mg of fingolimod, 16.6% with 1.25 mg of fingolimod, and 24.1% with placebo. Both fingolimod doses were superior to placebo with regard to MRI-related measures (number of new or enlarged lesions on T2-weighted images, gadolinium-enhancing lesions, and brain-volume loss; P<0.001 for all comparisons at 24 months). Causes of study discontinuation and adverse events related to fingolimod included bradycardia and atrioventricular conduction block at the time of fingolimod initiation, macular edema, elevated liver-enzyme levels, and mild hypertension. As compared with placebo, both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI. These benefits will need to be weighed against possible long-term risks (ClinicalTrials.gov number, NCT00289970) [2].

According to Luisetto et al. [3] wrote that

“We observed some relevant literature involving the immune system in brain development in order to verify relationship in pathogenesis of autism disorder. We think are relevant in this Pervasive developmental disorder: the time of expression, micro-environment, immunologic status and genetic profile. All these factors can give right response to the next research activities [3].”

**Discussion and Conclusion**

“We have seen from literature the relationship existing between systemic immune status and local situation like in brain tissue. We can consider under a toxicological view this kind of influences in order to re-consider some brain pathologies especially if time-age related. (Peaks age classes more involved in some neurologic pathologies). Local Flogosis and related immune reaction activation contribute in some brain pathology and this can be consider a sort of toxicological effect that must to be deeply investigated in order to discover the patho genetic moments and innovative pharmacological strategies.

Toxicology science can add to immunology and pathology to have a more complete vision in some brain pathology in time evolution and strategic opportunities. We have see in example that using fingolimod we have a reduction in lymphocytes activation and when discontinued this effect reduced (like a discontinue of a toxic substantial). Dose related and time related. FINGOLIMOD Significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI) in objective way. Concepts as toxical doses, time of exposition, cumulative dosage, kinetics, and when discontinued this effect reduced (like a discontinue of a toxic substantial). Dose related and time related. FINGOLIMOD Significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI) in objective way. Concepts as toxical doses, time of exposition, cumulative dosage, kinetics,
dynamics, metabolism iatrogenic ADME and other toxicological parameter can be usefully introduced also in neuro immune toxicology to adequately focus a physio-pathogenetic phenomena. The results related to the references cited show an specific effect of a systemic drugs in a local place as brain. We think that observing a specific side effect of a drug can be an right method to clear some interference between immunologic status and some development disorder.

**Clarifications**

This work has no any diagnostic or therapeutic intent, only to produce research hypotesys.

**References**

